Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Department of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Curr Pain Headache Rep. 2021 Mar 24;25(5):29. doi: 10.1007/s11916-021-00949-0.
Dual enkephalinase inhibitors (DENKIs) are pain medications that indirectly activate opioid receptors and can be used as an alternative to traditional opioids. Understanding the physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future.
DENKIs can be used as an alternative mode of analgesia for patients suffering from chronic pain by preventing the degradation of endogenous opioid ligands. By inhibiting the two major enkephalin-degrading enzymes (neprilysin and aminopeptidase N), DENKIs can provide analgesia with less adverse effects than nonendogenous opioids. The purpose of this paper is to review the current literature investigating DENKIs and explore their contribution to chronic pain management.
双重脑啡肽酶抑制剂 (DENKIs) 是一种可间接激活阿片受体的止痛药物,可作为传统阿片类药物的替代品。了解脑啡肽及其抑制剂的生理学和这些药物的药理学将有助于将来为慢性疼痛患者进行适当的临床应用。
DENKIs 可以通过防止内源性阿片配体降解,作为慢性疼痛患者的另一种镇痛方式。通过抑制两种主要的脑啡肽降解酶(脑啡肽酶和氨肽酶 N),DENKIs 可以提供比非内源性阿片类药物更少的不良反应的镇痛效果。本文的目的是综述目前关于 DENKIs 的文献,并探讨其对慢性疼痛管理的贡献。